Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
Journal: Radiology
Published: March 31, 2026
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology.
Journal: bioRxiv : the preprint server for biology
Published: February 23, 2026
Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 30, 2025
The Role of SPECT/CT in 177 Lu-PSMA-617 Theranostics: Case-based Review of Response and Progression Patterns.
Journal: Clinical nuclear medicine
Published: November 18, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 31, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 26, 2024
Showing 1-6 of 6
Last Updated: 09/26/2026